Follow Incyte to never miss an important update.
Mizuho Securities set its price target for the drugmaker at $148. This is higher than the average target of $137 across all analysts who follow the company. While the firm is optimistic, the stock's performance will likely depend on how well the company can grow its newer dermatology treatments. These new products need to generate enough sales to replace the revenue from its core cancer drug, which will lose its patent protection in 2028.
Source: Mizuho Securities
European regulators approved Povofortay for adults with moderate to severe hidradenitis suppurativa, a painful and long-term inflammatory skin condition. This makes it the first once-daily pill available in Europe for this specific condition, offering an alternative to existing injectable treatments.
This approval is a helpful step in the company's plan to move beyond its core cancer drugs. By expanding its dermatology portfolio, the business is building new sources of revenue to help offset the impact when its top-selling cancer drug, Jakafi, loses its patent protection in 2028.
Source: Business Wire
Incyte is starting a mid-stage study for its new immunotherapy, INCA33890, in patients with stage 2 or 3 colorectal cancer. The trial will use Natera's Signatera test, which looks for tiny amounts of cancer DNA in the blood to see if a treatment is working or if the cancer is returning.
This partnership is a step in Incyte's plan to grow beyond its core blood cancer business. Colorectal cancer is a much larger market than the rare disorders the company currently treats. Using advanced testing to identify which patients are most likely to benefit could help the drug move through the regulatory process faster, which is vital as Incyte prepares for its main drug to lose patent protection in 2028.
Source: Business Wire
Oppenheimer raised its rating on the stock to outperform on Friday. The move comes a day after the company reported that its newer skin treatments are growing quickly, which helps address concerns about older drugs losing their patent protection in a few years.
The firm set a price target of $144, which is about 18 percent higher than where the stock is currently trading. Other analysts also nudged their targets higher this week, bringing the average across all firms to $138.
Source: Oppenheimer
After Incyte reported its October results, we updated our fair value and cut our quality score to 3.1. We moved our rating to Watch and reset our expectations for how much profit the business keeps after spending on research. We have added the impact of one-time government legal settlements to what we track to better monitor underlying drug demand. We also added the cost and volatility of buying external drug technology to our analysis as the company works to replace revenue from its older blood cancer medicines.
Management consistently sets a beatable bar and clears it, with six beats in the last eight quarters. This pattern suggests the team has a firm handle on its growth and provides reliable forecasts.
| Expectation | |
|---|---|
| EPS | $1.91 |
| Revenue | $1.56B |